Taysha Gene Therapies have announced today that the very first patient with Rett Syndrome has now been dosed with with their gene therapy product TSHA-102.
The patient received the dose in Montreal, Canada and we’re excited to see that so far there have been no issues.
Reverse Rett was founded in 2010 to accelerate treatments and cures for Rett Syndrome.
The Taysha program and others are now coming to fruition because of academic programs and consortia which Reverse Rett has funded over the years through the US based Rett Syndrome Research Trust.
We’d like to take this moment to celebrate and thank all the amazing families, friends, donors and supporters of Reverse Rett who through fourteen years of blood, sweat and tears fundraising have helped bring us to this place in time.
We send lots of love, strength and good wishes to the brave patient and family who came forward to volunteer to be the first person in the world to trial gene therapy for Rett.
We expect further information from Taysha later in the summer.